Rapid switchover to carbamazepine using pharmacokinetic parameters

Epilepsia

Volumn 39, Issue 2, 1998, Pages 194-200

  Kanner, Andres M ^a,d,e   Bourgeois, Blaise F D ^b   Hasegawa, Hisanori ^a,d   Hutson, Paul ^c  

^a RUSH MEDICAL COLLEGE   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF WISCONSIN MADISON   (United States)

^d UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^e RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Carbamazepine; Pharmacodynamic cross tolerance; Pharmacokinetic cross tolerance; Rapid switchover

Indexed keywords

CARBAMAZEPINE; PHENOBARBITAL; PHENYTOIN; PRIMIDONE;

ADULT; AREA UNDER THE CURVE; ARTICLE; BRAIN DISEASE; CLINICAL ARTICLE; CONFUSION; DRUG BLOOD LEVEL; DRUG CROSS TOLERANCE; DYSPEPSIA; EPILEPSY; FEMALE; HUMAN; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK FACTOR; STEADY STATE;

ADULT; ANTICONVULSANTS; CARBAMAZEPINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; EPILEPSIES, PARTIAL; FEMALE; HUMANS; MALE; PHENYTOIN; PILOT PROJECTS; PRIMIDONE; THERAPEUTIC EQUIVALENCY;

EID: 0031906881     PISSN: 00139580     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1528-1157.1998.tb01358.x     Document Type: Article

References (32)

1. Porter RJ. How to initiate and maintain carbamazepine therapy in children and adults. Epilepsia 1987;28(suppl 3):S59-63.
2. Loiseau P, Duche B. Carbamazepine: clinical use. In: Levy RH, Mattson RH, Meldrum BH, eds. Antiepileptic drugs 4th Ed. New York: Raven Press, 1995;543-54.
3. Bourgeois B, Lüders H, Morris H, Dinner D, Van Ness P, Kanner A. Rapid change-over to carbamazepine monotherapy using single dose pharmacokinetics. Epilepsia 1989;30:662.
4. Levy RH, Wurden CJ. Carbamazepine: interaction with other drugs. In: Levy RH, Mattson RH, Meldrum BH, eds. Antiepileptic drugs. 4th Ed. New York: Raven Press, 1995;543-54.
5. Chadwick D, Shaw MDM, Foy P, Rawlins MD, Turnbull DM. Serum anticonvulsant concentrations and the risk of drug induced eruptions. J Neurol Neurosurg Psychiatr 1984;47:642-4.
6. Hartley R, Lucock M, Cookman JR, et al. High performance liquid Chromatographic determination of carbamazepine and carbamazepine 10, 11-epoxide in plasma and saliva following solid phase extraction. J Chromatogr 1986;380:347-56.
7. Schaffler L, Bourgeois BFD, Lüders HO. Rapid reversibility of autoinduction of carbamazepine metabolism after temporary discontinuation. Epilepsia 1994;35:195-8.
8. Bourgeois BFD. Important pharmacokinetic properties of antiepileptic drugs. Epilepsia 1995;36(suppl 5):S1-7.
9. Scheyer RD, Cramer JA, Mattson RH. A pharmacodynaymic approach to the estimate of carbamazepine autoinduction. J Pharm Sci 1994;84:4:491-4.
10. Scheyer RD and Mattson RH. A method for prediction of phenytoin levels in the acute clinical settings. Comput Biomed Res 1991; 24:564-75.
11. Kerr BM and Levy RH. Carbamazepine epoxide. In: Levy RH, Mattson RH, Meldrum BH, eds. Antiepileptic drugs 4th Ed. New York: Raven Press, 1995:529-42.
12. Christiansen J, Dam M. Influence of phenobarbital and diphenylhydantoin on plasma carbamazepine levels in patients with epilepsy. Acta Neurol Scand 1973;49:543-6.
13. Christiansen J, Dam M. Drug interactions in epileptic patients. In: Schneider H, Janz D, Gardner-Thorpe C, Meinardi H, Sherwin AL, eds. Clinical pharmacology of antiepileptic drugs. Berlin: Springer-Verlag, 1975:197-200.
14. Battino D, Bossi L, Croci D, Franceschetti S, Gomeni C, Moise A, Vitali A. Carbamazepine plasma levels in children and adults: influence of age, dose, and associated therapy. Ther Drug Monit 1980;2:315-22.
15. Bertilsson L, Tomson T. Clinical pharmacokinetics and pharmacological effects of carbamazepine and carbamazepine 10-11-epoxide. Clin Pharmacokinet 1986;11:177-98.
16. Mattson RH, Cramer JA, Collins JF, et al. Comparison of carbamazepine, phenobarbital, phenytoin and primidone in partial and secondarily generalized tonic-clonic seizures. N Engl J Med 1985;313:145-51.
17. Pellock JM. Carbamazepine side effects in children and adults. Epilepsia 1987;28(suppl. 3):S64-70.
18. Smith DB, Mattson RH, Cramer JA, Collins JF, Novelli RA, Craft B, and the Veterans Administration Epilepsy Cooperative Study Group. Results of Nationwide Veterans Administration Cooperative Study comparing the efficacy and toxicity of carbamazepine, phenobarbital, phenytoin and primidone. Epilepsia 1987;28(suppl. 3):s50-8.
19. Collaborative Group for Epidemiology of Epilepsy. Adverse reactions to antiepileptic drugs: a follow-up study of 355 patients with chronic antiepileptic drug treatment. Epilepsia 1988;29:787-92.
20. Herranz JL, Armijo JA, Arteaga R. Clinical side effects of phenobarbital, primidone, phenytoin, carbamazepine and valproate during monotherapy in children. Epilepsia 1988;29:794-804.
21. Kutt S, Solomon G, Wasterlain C, Peterson H, Louis S, Carruthers R. Carbamazepine in difficult-to-control epileptic outpatients. Acta Neurol Scand 1975;suppl 60:27-32.
22. Heller AJ, Chesterman P, Elwes RD, et al. Phenobarbitone, phenytoin, carbamazepine or sodium valproate for newly diagnosed adult epilepsy: a randomized comparative monotherapy trial. J Neurol Neurosurg Psychiatr 1995;58:44-50.
23. Mattson RH, Cramer JA, Collins JF, and the Department of Veterans Affairs Epilepsy Cooperative Study Group. A comparison of valproate with carbamazepine for the treatment of complex partial seizures and secondarily generalized tonic-clonic seizures in adults. N Engl J Med 1992;327:765-71.
24. Reynolds EH. Chronic antiepilepsy toxicity: a review. Epilepsia 1975;16:319-52.
25. Cereghino JJ, Brock JT, Van Meter JC, Penry JK, Smith LD, White BG. Carbamazepine for epilepsy: a controlled prospective evaluation. Neurology 1974;24:401-10.
26. Bourgeois BFD. Individual and crossed tolerance to the anticonvulsant effect and neurotoxicity of phenobarbital and primidone in mice. In: Frey HH, Fröscher W, Koella WP, Meinardi H, eds. Tolerance to beneficial and adverse effects of antiepileptic drugs. New York: Raven Press, 1986:17-24.
27. Bourgeois BFD. Primidone. In: Wyllie E, ed. The treatment of epilepsy: principles and practice. Philadelphia: Lea and Fibiger, 1993:909-14.
28. Leppik IE, Cloyd JC, Miller K. Development of tolerance to the side effects of primidone. Ther Drug Monit 1984;6:189-91.
29. Koella WP. Tolerance: its various forms and their nature. In: Frey HH, Fröscher W, Koella WP, Meinardi H, eds. Tolerance to beneficial and adverse effects of antiepileptic drugs. New York: Raven Press, 1986:1-6.
30. Ferrendelli JA, Mathews GC. Neuropharmacology of antiepileptic medications: mechanisms of action. In: Wyllie E, ed. The treatment of epilepsy: principles and practice. Philadelphia: Lea and Febiger, 1993:735-42.
31. Duncan JS, Shorvon SD, Trimble MR. Discontinuation of phenytoin, carbamazepine and valproate in patients with active epilepsy. Epilepsia 1990;31:324-33.
32. Cramer JA, Mattson RH. Phenobarbital: toxicity. In: Levy RH, Mattson RH, Meldrum BH, eds. Antiepileptic drugs. 4th Ed. New York: Raven Press, 1995:409-20.